• Defense of medical device manufacturer in hernia mesh litigation.
    • Represented a major pharmaceutical company in mass tort litigation involving medication used to prevent formation of blood clots.  This representation involved trial strategy and defense of cases in the Mass Tort program of the Philadelphia Court of Common Pleas.
    • Appellate counsel for major pharmaceutical company in mass tort litigation involving pediatric use of antipsychotic medication.
    • Represented a major pharmaceutical company in its Zoloft multi-district litigation in the Eastern District of Pennsylvania in which plaintiffs allege an increased risk of birth defects from use of SSRI medications. 
    • Represented major American sports corporation in the multi-district litigation proceeding pending in the Eastern District of Pennsylvania, In re National Football League Players’ Concussion Injury Litigation.
    • Representation of two major pharmaceutical companies in Hormone Therapy litigation, overseeing mass tort proceedings in the Philadelphia Court of Common Pleas (PCCP) and handling court appearances, trial preparation, briefing and legal strategy in cases nationwide. 
    • Defended a major pharmaceutical company in federal multi-district litigation and state court product liability litigation related to an antipsychotic medication, playing a lead role in the preparation and defense of company witnesses and in briefing strategy and in the coordination of U.S. and Canadian litigation. 
    • Vanderbilt University, B.A., 1978, Phi Beta Kappa , summa cum laude
    • Temple University Beasley School of Law, J.D., note and comment editor of the Temple University Law Review , magna cum laude
    • Pennsylvania
    • Supreme Court of Pennsylvania
    • United States District Court for the Eastern District of Pennsylvania
    • United States Court of Appeals for the Third Circuit
    • Views from the Plaintiff and Defense Bar on the New Rules — HarrisMartin Complex Litigation Conference: Examining the Court's New Mass Tort and Asbestos Protocols, Philadelphia, PA (June 5, 2012)
    • Minimizing Purchaser/Consumer Fraud Class Action Off-Label Liabilities — ACI 6th Annual Pharmaceutical Counsel's Guide to Off-Label Communications, Philadelphia, PA (July 15, 2009)
    • Optimizing the Effectiveness of Multiple Communication Channels While Minimizing Off-Label Promotion Risks — Third Annual Medical Device and Pharmaceutical Counsel's Guide to Off-Label Communications, Chicago, IL (September 13, 2006)